Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415)

INTRODUCTION: Esophageal adenocarcinomas commonly express the Epidermal Growth Factor Receptor (EGFR). This trial assessed the six month overall survival probability in metastatic esophageal cancer patients treated with cetuximab as second line therapy. METHODS: This was a multicenter, open-label ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gold, Philip J., Goldman, Bryan, Iqbal, Syma, Leichman, Lawrence P., Zhang, Wu, Lenz, Heinz-Josef, Blanke, Charles D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2928397/
https://ncbi.nlm.nih.gov/pubmed/20631636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181e77a92
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados